	US 11,865,215 B2
	Tablet compositions comprising abiraterone acetate
Sara Fradera Gelabert, Sant Boi de Llobregat (ES); Manuel Gago Guillan, Sant Boi de Llobregat (ES); Lisardo Alvarez Fernandez, Sant Boi de Llobregat (ES); and Rohit Kumar, Sant Boi de Llobregat (ES)
Assigned to Synthon B.V., Nijmegen (NL)
Appl. No. 17/044,698
Filed by SYNTHON B.V., Nijmegen (NL)
PCT Filed Jan. 25, 2019, PCT No. PCT/EP2019/051921 § 371(c)(1), (2) Date Oct. 1, 2020, PCT Pub. No. WO2019/206472, PCT Pub. Date Oct. 31, 2019.
Claims priority of application No. 18169623 (EP), filed on Apr. 26, 2018.
Prior Publication US 2021/0038525 A1, Feb. 11, 2021
Int. Cl. A61K 9/28 (2006.01); A61K 9/20 (2006.01); A61K 31/58 (2006.01)

CPC A61K 9/2893 (2013.01) [A61K 9/205 (2013.01); A61K 9/2009 (2013.01); A61K 9/2013 (2013.01); A61K 9/2072 (2013.01); A61K 9/2095 (2013.01); A61K 31/58 (2013.01)]

20 Claims

1. A tablet composition comprising granules and one or more extragranular pharmaceutical excipients, wherein the granules comprise intragranularly:

a) abiraterone acetate in an amount of from 40% to 60% by weight based on the total weight of the composition;

b) colloidal anhydrous silica in an amount of from 0.1% to 5% by weight based on the total weight of the composition; and

c) surfactant in an amount of from 0.1% to 3% by weight based on the total weight of the composition,

wherein the extragranular excipients comprise surfactant in an amount of from 3% to 7% by weight based on the total weight of the composition, and a diluent in an amount from 10% to 30% by weight based on the total weight of the composition, wherein said diluent is microcrystalline cellulose (MCC).